Yahoo
Stockholm - Delayed Quote SEK

CellaVision AB (publ) (CEVI.ST)

187.80 +13.00 (+7.44%)
At close: 5:29:47 PM GMT+1
CEVI.ST Q3 2026 earnings call
Replay the call for the latest insights.
Chart Range Bar
Loading chart for CEVI.ST
  • Previous Close 174.80
  • Open 186.00
  • Bid 183.80 x --
  • Ask 184.20 x --
  • Day's Range 178.20 - 188.00
  • 52 Week Range 117.60 - 191.20
  • Volume 445,626
  • Avg. Volume 25,999
  • Market Cap (intraday) 4.479B
  • Beta (5Y Monthly) 0.92
  • PE Ratio (TTM) 35.50
  • EPS (TTM) 5.29
  • Earnings Date Oct 29, 2026
  • Forward Dividend & Yield 2.75 (1.57%)
  • Ex-Dividend Date Apr 29, 2026
  • 1y Target Est 181.67

CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems; and DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and CellaVision DM9600 to automate and simplify the process of performing blood and body fluid differentials. In addition, the company's CellaVision Bone Marrow Aspirate Application enables laboratories to automate, standardize, and simplify morphological examination of bone marrow aspirate samples; CellaVision Peripheral Blood Application enables laboratories to automate, standardize and simplify morphological examination like peripheral blood smears; CellaVision Advanced RBC Application performs a more comprehensive examination for red blood cell morphology; CellaVision Body Fluid Application is for examination body fluid preparations; CellaVision CellAtlas, a library of blood cell images and descriptions created by digital cell morphology experts; CellaVision Review Software removes restrictive constraints from smear review process and performs better; CellaVision Server Software creates a single streamlined workflow within one or multiple testing sites; and CellaVision VET is a veterinary lab. It sells its products to hospitals and commercial laboratories. The company was incorporated in 1994 and is based in Lund, Sweden.

www.cellavision.com

251

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Performance Overview

Trailing total returns as of 10/29/2026, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

CEVI.ST
22.12%
OMX Stockholm 30 Index (^OMX)
13.80%

1-Year Return

CEVI.ST
4.68%
OMX Stockholm 30 Index (^OMX)
17.61%

3-Year Return

CEVI.ST
52.70%
OMX Stockholm 30 Index (^OMX)
60.07%

5-Year Return

CEVI.ST
48.78%
OMX Stockholm 30 Index (^OMX)
43.22%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 199.5M
Earnings 40.17M
Profit Margin 20.13%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
50M
100M
150M
14.0%
16.0%
18.0%
20.0%

Analyst Insights

View More

Analyst Price Targets

160.00 Low
181.67 Average
187.80 Current
200.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
As of 10/28/2026
  • Market Cap

    4.17B

  • Enterprise Value

    4.05B

  • Trailing P/E

    32.31

  • Forward P/E

    24.94

  • PEG Ratio (current)

    6.53

  • Price/Sales (ttm)

    5.64

  • Price/Book (mrq)

    4.71

  • Enterprise Value/Revenue

    5.48

  • Enterprise Value/EBITDA

    24.64

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.46%

  • Return on Assets (ttm)

    9.39%

  • Return on Equity (ttm)

    15.11%

  • Revenue (ttm)

    739.15M

  • Net Income Avi to Common (ttm)

    129.09M

  • Diluted EPS (ttm)

    5.29

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    172.19M

  • Total Debt/Equity (mrq)

    5.90%

  • Levered Free Cash Flow (ttm)

    63.92M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: